Compare Avantis US Small Cap Value ETF (AVUV) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Stryker Corporation — how do they compare? Avantis US Small Cap Value ETF trades at $124.88, while Stryker Corporation trades at $309.09 (market cap $119.25B). The key difference: Stryker Corporation pays a 1.13% dividend while Avantis US Small Cap Value ETF pays none, and Avantis US Small Cap Value ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| AVUV | SYK | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $124.94 | $403.53 |
52-Week Low | $90.37 | $282.58 |
Market Cap | — | $119.25B |
Enterprise Value | — | $131.01B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $123.97, up 0.02% on the day, with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. small-cap value stocks, which have outperformed growth peers in 2026, driven by shifting rate expectations. Recent news highlights its role in diversifying tech-heavy portfolios and capturing the small-cap value premium.
Outlook remains positive as small-cap value gains favor amid economic shifts, though risks include higher volatility and sensitivity to interest rates. The fund offers growth potential but requires tolerance for the inherent risks of smaller companies.
Stryker (SYK) trades at $331.45, up 0.51% today, with strong analyst support (74% buy ratings) and a consensus price target of $388.44. The stock shows bullish technical signals despite a recent Q1 2026 earnings miss attributed to a temporary cyber disruption. Fundamentals remain solid with 2025 revenue of $25.12B, net income margin of 13.21%, and robust cash flow generation of $5.04B from operations.
Outlook remains positive with maintained full-year guidance and healthy end-market demand. Investment opportunity lies in the valuation discount to historical averages and innovation-driven growth. Key risks include cybersecurity vulnerabilities and competitive pressures in the medtech sector. The stock offers potential upside of 17% to consensus target with dividend stability as a Dividend Aristocrat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
